Fulgent Genetics Stock Investor Sentiment

FLGT Stock  USD 18.95  0.17  0.91%   
Slightly above 51% of Fulgent Genetics' investor base is interested to short. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that many investors are impartial at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
  

Fulgent Genetics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Fulgent Genetics Maximum Pain Price Across January 17th 2025 Option Contracts

Fulgent Genetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Fulgent Genetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Fulgent Genetics' options.
over a month ago at gurufocus.com         
Fulgent Genetics Inc Q3 2024 Earnings Call Highlights Strategic Growth Amid Revenue Decline
Gurufocus Stories at Macroaxis
over two months ago at businesswire.com         
Fulgent Reports Third Quarter 2024 Financial Results
businesswire News
over two months ago at investing.com         
Fulgent Genetics earnings beat by 0.46, revenue fell short of estimates
Investing News at Macroaxis
over two months ago at seekingalpha.com         
Fulgent Genetics Non-GAAP EPS of 0.31 beats by 0.46, revenue of 71.7M in-line
seekingalpha News
over two months ago at seekingalpha.com         
Fulgent Genetics Non-GAAP EPS of 0.31 beats by 0.46, revenue of 71.74M in-line
seekingalpha News
over two months ago at gurufocus.com         
Fulgent Genetics Inc Reports Q3 2024 Earnings Non-GAAP EPS of 0.31, Revenue at 71.7 Million
Gurufocus Stories at Macroaxis
over two months ago at finance.yahoo.com         
Fulgent Genetics, Inc. Surpasses Q3 Earnings and Revenue Estimates
Yahoo News
over two months ago at thelincolnianonline.com         
Fulgent Genetics Releases FY24 Earnings Guidance
news
over two months ago at fool.com         
Breakfast News Action Packed
fool News
over two months ago at seekingalpha.com         
Fulgent Genetics Q3 2024 Earnings Preview
seekingalpha News
over two months ago at businesswire.com         
Fulgent to Participate in Upcoming Conferences
businesswire News
over two months ago at simplywall.st         
Positive week for Fulgent Genetics, Inc. institutional investors who lost 20 percent over the past y...
Simply Wall St News at Macroaxis
over two months ago at finance.yahoo.com         
Disposition of 1337 shares by Ming Hsieh of Fulgent Genetics at 21.61 subject to Rule 16b-3
Yahoo News
over two months ago at finance.yahoo.com         
Fulgent Genetics Surges 5.8 percent Is This an Indication of Further Gains?
Yahoo News
over two months ago at businesswire.com         
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary C...
businesswire News
Far too much social signal, news, headlines, and media speculation about Fulgent Genetics that are available to investors today. That information is available publicly through Fulgent media outlets and privately through word of mouth or via Fulgent internal channels. However, regardless of the origin, that massive amount of Fulgent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fulgent Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fulgent Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fulgent Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fulgent Genetics alpha.

Fulgent Genetics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Gao Hanlin of 27 shares of Fulgent Genetics subject to Rule 16b-3
10/14/2024
2
Disposition of 4345 shares by Jian Xie of Fulgent Genetics at 19.42 subject to Rule 16b-3
10/25/2024
3
Disposition of tradable shares by Gao Hanlin of Fulgent Genetics at 20.27 subject to Rule 16b-3
10/30/2024
4
Fulgent to Participate in Upcoming Conferences
11/05/2024
5
Fulgent Genetics Downgraded to Sell Rating by StockNews.com
11/12/2024
6
Fulgent Genetics Hits New 52-Week Low Heres What Happened
11/19/2024
7
Fulgent Genetics, Inc. Among the Best Genomics Stocks to Buy Right Now
11/20/2024
8
Gene Panel Market to Surpass USD 11.75 Billion by 2031 SkyQuest Technology
11/22/2024
9
Disposition of 689 shares by Jian Xie of Fulgent Genetics at 18.2593 subject to Rule 16b-3
11/25/2024
10
Fulgent Genetics CEO Ming Hsieh sells 40,663 in stock
11/27/2024
11
Disposition of 1553 shares by Paul Kim of Fulgent Genetics at 18.3 subject to Rule 16b-3
11/29/2024
12
Disposition of 1373 shares by Gao Hanlin of Fulgent Genetics at 19.4999 subject to Rule 16b-3
12/03/2024
13
Fulgent Genetics chief scientific officer sells 26,773 in stock
12/04/2024
14
Wall Street Analysts Predict a 31.06 percent Upside in Fulgent Genetics Heres What You Should Know
12/09/2024
15
Acquisition by Jian Xie of 27 shares of Fulgent Genetics subject to Rule 16b-3
12/10/2024
16
Fulgent Genetics, Inc. Shares Purchased by BNP Paribas Financial Markets - MarketBeat
12/11/2024

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.